Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$118.01 USD

118.01
3,976,367

-1.06 (-0.89%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $117.96 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novo Nordisk (NVO) Stock Moves -0.89%: What You Should Know

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $118.01, denoting a -0.89% change from the preceding trading day.

Kinjel Shah headshot

Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors

RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.

PFE vs. NVO: Which Stock Is the Better Value Option?

PFE vs. NVO: Which Stock Is the Better Value Option?

Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?

Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study

2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.

The Zacks Analyst Blog Highlights Broadcom, Novo Nordisk, ConocoPhillips, Smith-Midland Corp. and Tredegar

Broadcom, Novo Nordisk, ConocoPhillips, Smith-Midland Corp. and Tredegar are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Research Reports for Broadcom, Novo Nordisk & ConocoPhillips

Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Novo Nordisk A/S (NVO) and ConocoPhillips (COP), as well as two micro-cap stocks Smith-Midland Corp. (SMID) and Tredegar Corp. (TG).

Novo Nordisk (NVO) Rises Higher Than Market: Key Facts

Novo Nordisk (NVO) closed at $125.44 in the latest trading session, marking a +1.41% move from the prior day.

VTYX Stock Rises on Strategic Equity Investment Deal With SNY

Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.

NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study

Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Ahan Chakraborty headshot

NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.

NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms and improved physical function.

Kinjel Shah headshot

Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?

SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.

Kinjel Shah headshot

Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Novo Nordisk (NVO) Gains As Market Dips: What You Should Know

Novo Nordisk (NVO) concluded the recent trading session at $132.06, signifying a +0.05% move from its prior day's close.

Sweta Killa headshot

Tap the Weight-Loss Drug Market With These ETFs

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

Kinjel Shah headshot

Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?

Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.

Novo Nordisk (NVO) Outperforms Broader Market: What You Need to Know

Novo Nordisk (NVO) reachead $136.66 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.

Kinjel Shah headshot

NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.

PFE or NVO: Which Is the Better Value Stock Right Now?

PFE vs. NVO: Which Stock Is the Better Value Option?